Atlas Private Wealth Advisors reduced its stake in shares of The Clorox Company (NYSE:CLX - Free Report) by 47.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,392 shares of the company's stock after selling 7,604 shares during the quarter. Atlas Private Wealth Advisors' holdings in Clorox were worth $1,236,000 as of its most recent SEC filing.
Other hedge funds have also recently bought and sold shares of the company. Redwood Park Advisors LLC bought a new position in Clorox in the 4th quarter valued at $26,000. Millstone Evans Group LLC bought a new position in shares of Clorox in the fourth quarter valued at about $31,000. Wood Tarver Financial Group LLC acquired a new position in Clorox during the 4th quarter worth about $31,000. Asset Planning Inc acquired a new position in Clorox during the 4th quarter worth about $32,000. Finally, GKV Capital Management Co. Inc. bought a new stake in Clorox during the 4th quarter worth about $32,000. 78.53% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Clorox
In related news, Director Pierre R. Breber purchased 4,000 shares of the stock in a transaction on Wednesday, May 7th. The shares were purchased at an average cost of $136.57 per share, with a total value of $546,280.00. Following the acquisition, the director now directly owns 4,000 shares in the company, valued at $546,280. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.57% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on the stock. Wells Fargo & Company dropped their target price on shares of Clorox from $145.00 to $142.00 and set an "equal weight" rating for the company in a research note on Tuesday, May 6th. Evercore ISI set a $140.00 price objective on shares of Clorox and gave the stock an "underperform" rating in a research report on Tuesday, May 6th. Morgan Stanley decreased their price objective on Clorox from $165.00 to $150.00 and set an "equal weight" rating on the stock in a research report on Tuesday, May 6th. Barclays dropped their target price on Clorox from $134.00 to $129.00 and set an "underweight" rating for the company in a research report on Wednesday, May 7th. Finally, Citigroup decreased their price target on Clorox from $165.00 to $150.00 and set a "neutral" rating on the stock in a report on Monday, April 14th. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Hold" and an average price target of $151.23.
Read Our Latest Report on Clorox
Clorox Stock Performance
NYSE CLX traded down $1.33 on Wednesday, hitting $120.77. 1,722,654 shares of the stock were exchanged, compared to its average volume of 1,362,961. The business's fifty day moving average is $134.30 and its 200 day moving average is $147.74. The Clorox Company has a 52 week low of $120.71 and a 52 week high of $171.37. The company has a market capitalization of $14.88 billion, a PE ratio of 21.68, a P/E/G ratio of 2.80 and a beta of 0.54. The company has a debt-to-equity ratio of 13.07, a current ratio of 0.74 and a quick ratio of 0.44.
Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). The business had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.74 billion. Clorox had a return on equity of 324.23% and a net margin of 9.89%. The company's revenue for the quarter was down 8.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.71 EPS. Research analysts anticipate that The Clorox Company will post 7.15 EPS for the current fiscal year.
Clorox Profile
(
Free Report)
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.
Further Reading
Before you consider Clorox, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clorox wasn't on the list.
While Clorox currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
